Abstract |
The aim of this study is to determine the efficacy of a potent and specific vascular adhesive protein-1/ semicarbazide-sensitive amine oxidase ( VAP-1/SSAO) inhibitor, LJP 1207, as a potential antiangiogenic and anti-inflammatory agent in the therapy of corneal neovascularization. Corneal neovascularization was induced with intrastromal suturing in rabbits (n = 20). Topical treatment with VAP-1/SSAO inhibitor LJP 1207 (n = 5, 4 times a day), bevacizumab (n = 5, daily), their combination (n = 5) and vehicle only (n = 5, 4 times a day) were applied postoperatively for 2 weeks. The development and extent of corneal neovascularization were evaluated by digital image analysis. At the end of the observation period, the level of corneal and serum VAP-1/SSAO activity was measured fluorometrically and radiochemically. The corneal VAP-1/SSAO activity was significantly elevated in the suture-challenged vehicle-treated group (3,075 ± 1,009 pmol/mg/h) as compared to unoperated controls (464.2 ± 135 pmol/mg/h, p < 0.001). Treatment with LJP 1207 resulted in slower early phase neovascularization compared to vehicle-treated animals (not significant). At days 7-14, there was no significant difference in the extent of corneal neovascularization between inhibitor- and vehicle-treated corneas, even though inhibitor treatment caused a normalization of corneal VAP-1/SSAO activity (885 ± 452 pmol/mg/h). Our results demonstrate that the significant elevation of VAP-1/SSAO activity due to corneal injury can be prevented with VAP-1/SSAO inhibitor LJP 1207 treatment. However, normalization of VAP-1/SSAO activity in this model does not prevent the development of corneal neovascularization.
|
Authors | Anna Énzsöly, Katalin Markó, Tamás Tábi, Éva Szökő, Romána Zelkó, Miklós Tóth, J Mark Petrash, Péter Mátyus, János Németh |
Journal | Journal of neural transmission (Vienna, Austria : 1996)
(J Neural Transm (Vienna))
Vol. 120
Issue 6
Pg. 969-75
(Jun 2013)
ISSN: 1435-1463 [Electronic] Austria |
PMID | 23397320
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Anti-Inflammatory Agents
- Antibodies, Monoclonal, Humanized
- Hydrazines
- N'-(2-phenylallyl)hydrazine
- Bevacizumab
- Amine Oxidase (Copper-Containing)
|
Topics |
- Amine Oxidase (Copper-Containing)
(metabolism)
- Angiogenesis Inhibitors
(therapeutic use)
- Animals
- Anti-Inflammatory Agents
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Bevacizumab
- Cornea
(enzymology)
- Corneal Neovascularization
(blood, drug therapy, etiology, metabolism)
- Disease Models, Animal
- Drug Interactions
- Hydrazines
(blood, therapeutic use)
- Male
- Rabbits
- Suture Techniques
(adverse effects)
- Time Factors
|